-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the promotion and implementation of policies such as the normalization of centralized procurement and the outflow of prescriptions, the concentration of the pharmaceutical retail industry has continued to increase.
Wait for the uninterrupted movement to realize the expansion of the territory
.
Dahu shares announced on the evening of October 12 that its wholly-owned subsidiary Dehai Medical Trade and its wholly-owned subsidiary Dehai Pharmacy and Yifeng Pharmacy signed the "Asset Acquisition Framework Agreement" to sell Dehai Pharmacy’s name All 12 directly operated pharmacies in the camp
.
It can be seen that the pace of acquisition of Yifeng Pharmacy has taken another step
.
According to data, Dehai Pharmacies are mainly distributed in Changde City, Li County and Taoyuan County of Hunan Province.
The 12 directly-operated pharmacies under its name have a total operating area of approximately 1045.
5 square meters
.
Financial data show that in 2020, the net assets of these stores will be 1.
645 million yuan, operating income will be 9.
8 million yuan, and net profit will be 47,000 yuan; the net assets for the first six months of 2021 will be 1.
55 million yuan, and operating income will be 3.
92 million yuan.
, The unaudited net profit is -93,000 yuan
.
Regarding this transaction, Dehai Pharmacy stated in the announcement that Dehai Pharmacy is subject to fierce market competition pressure in the same region and the impact of the epidemic on physical stores.
The cost of acquiring new growth points is higher than its exit cost.
The benefits of continuing operations are not sufficient to meet the needs of the company's business development
.
The sale of relevant assets of Dehai Pharmacy may be helpful to the company in optimizing the allocation of resources and improving the company's operating conditions
.
Hunan Province is the base camp of Yifeng Pharmacy, which accounts for more than 40% of its revenue in Central and Southern China.
The other giant that competes with it is the ordinary people.
With the implementation of the new acquisition of Yifeng Pharmacy, it is in Hunan The competitiveness of the market may also be improved to a certain extent
.
It is worth mentioning that in addition to the Hunan market, the new signal released by Yifeng Pharmacy in the Hubei market, another important revenue region, has also attracted the attention of the industry.
.
According to news from the Hubei Food and Drug Administration on October 11, the Hubei Food and Drug Administration mentioned in its reply to Yifeng’s “Application for Cross-Administrative Area Mergers and Acquisitions of Other Retail Chain Companies to Apply for the Issuance of Business Licenses for Retail Chain Enterprises”: “Cross-provincial or provincial Pharmaceutical retail chain enterprises within the province merge and reorganize other pharmaceutical retail chain enterprises in our province, and the "Pharmaceutical Business License" of the
acquired pharmaceutical retail chain enterprises can be cancelled .
The merged pharmaceutical retail chain enterprises can no longer retain the original drug distribution center, and the current drug retail chain The headquarters of chain enterprises have unified management to carry out drug storage and distribution; when drug retail chain enterprises carry out acquisitions, mergers, reorganizations and other activities, the business entity of the enterprise changes, and the DNA drug business address and licensing conditions have not actually changed, the on-site inspection may not be carried out
.
" The industry believes that from the above-mentioned interaction, Yifeng Pharmacy may plan to start a new operation in the Hubei market
.
And this seems to be in line with Yifeng's expansion plan for the next three years, that is, "the rate of opening stores in the future will be greater than or equal to 2,000 stores per year
.
" In addition, the central and southern region has always been an area that Yifeng Pharmacy pays attention to
.
According to relevant data, the number of Yifeng stores in Central and South China has increased from 559 in 2015 to 2,858 by the end of 2020, an increase of more than 2,000 in five years
.
In addition, since 2021, it is still expanding its territory in Central and South China.
According to data from the mid-year report, Yifeng Pharmacy opened 569 new stores in the first half of the year.
Among them, the number of new stores in Central and South China, including Hubei, reached 507
.
Wait for the uninterrupted movement to realize the expansion of the territory
.
Dahu shares announced on the evening of October 12 that its wholly-owned subsidiary Dehai Medical Trade and its wholly-owned subsidiary Dehai Pharmacy and Yifeng Pharmacy signed the "Asset Acquisition Framework Agreement" to sell Dehai Pharmacy’s name All 12 directly operated pharmacies in the camp
.
It can be seen that the pace of acquisition of Yifeng Pharmacy has taken another step
.
According to data, Dehai Pharmacies are mainly distributed in Changde City, Li County and Taoyuan County of Hunan Province.
The 12 directly-operated pharmacies under its name have a total operating area of approximately 1045.
5 square meters
.
Financial data show that in 2020, the net assets of these stores will be 1.
645 million yuan, operating income will be 9.
8 million yuan, and net profit will be 47,000 yuan; the net assets for the first six months of 2021 will be 1.
55 million yuan, and operating income will be 3.
92 million yuan.
, The unaudited net profit is -93,000 yuan
.
Regarding this transaction, Dehai Pharmacy stated in the announcement that Dehai Pharmacy is subject to fierce market competition pressure in the same region and the impact of the epidemic on physical stores.
The cost of acquiring new growth points is higher than its exit cost.
The benefits of continuing operations are not sufficient to meet the needs of the company's business development
.
The sale of relevant assets of Dehai Pharmacy may be helpful to the company in optimizing the allocation of resources and improving the company's operating conditions
.
Hunan Province is the base camp of Yifeng Pharmacy, which accounts for more than 40% of its revenue in Central and Southern China.
The other giant that competes with it is the ordinary people.
With the implementation of the new acquisition of Yifeng Pharmacy, it is in Hunan The competitiveness of the market may also be improved to a certain extent
.
It is worth mentioning that in addition to the Hunan market, the new signal released by Yifeng Pharmacy in the Hubei market, another important revenue region, has also attracted the attention of the industry.
.
According to news from the Hubei Food and Drug Administration on October 11, the Hubei Food and Drug Administration mentioned in its reply to Yifeng’s “Application for Cross-Administrative Area Mergers and Acquisitions of Other Retail Chain Companies to Apply for the Issuance of Business Licenses for Retail Chain Enterprises”: “Cross-provincial or provincial Pharmaceutical retail chain enterprises within the province merge and reorganize other pharmaceutical retail chain enterprises in our province, and the "Pharmaceutical Business License" of the
acquired pharmaceutical retail chain enterprises can be cancelled .
The merged pharmaceutical retail chain enterprises can no longer retain the original drug distribution center, and the current drug retail chain The headquarters of chain enterprises have unified management to carry out drug storage and distribution; when drug retail chain enterprises carry out acquisitions, mergers, reorganizations and other activities, the business entity of the enterprise changes, and the DNA drug business address and licensing conditions have not actually changed, the on-site inspection may not be carried out
.
" The industry believes that from the above-mentioned interaction, Yifeng Pharmacy may plan to start a new operation in the Hubei market
.
And this seems to be in line with Yifeng's expansion plan for the next three years, that is, "the rate of opening stores in the future will be greater than or equal to 2,000 stores per year
.
" In addition, the central and southern region has always been an area that Yifeng Pharmacy pays attention to
.
According to relevant data, the number of Yifeng stores in Central and South China has increased from 559 in 2015 to 2,858 by the end of 2020, an increase of more than 2,000 in five years
.
In addition, since 2021, it is still expanding its territory in Central and South China.
According to data from the mid-year report, Yifeng Pharmacy opened 569 new stores in the first half of the year.
Among them, the number of new stores in Central and South China, including Hubei, reached 507
.
